It also provides for an exclusive license in the United States,
Canada and Mexico to obtain regulatory approvals and then market VesCell stem cell therapy for the treatment of peripheral artery disease.
As part of the change in strategy to the Stem Cell Business as further described below under Item 5.02, Scott Massey, the former President, Chief Executive Officer and Director of the Company, and Phillips N.